CStone Pharmaceuticals Launches First Commercial Batch of Gavreto in China Following NRDL Inclusion
CStone Pharmaceuticals (HKG: 2616) announced the first batch manufacturing and release of its Gavreto (pralsetinib...
NHSA Launches 2026 NRDL Adjustment with Expanded Eligibility Criteria and Revised Weight Standards
The National Healthcare Security Administration (NHSA) has released its draft 2026 Work Plan for Adjusting...
Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
Zhejiang Wenda Pharmaceutical Technology Co., Ltd. announced it has received Breakthrough Therapy Designation (BTD) from...
European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
The European Commission (EC) granted marketing authorization this week for Bristol-Myers Squibb‘s (BMS, NYSE: BMY)...
CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
Shanghai CureGene Pharmaceutical Co., Ltd. announced the completion of its Series C financing round, raising...
Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis
Keymed Biosciences Inc. (HKG: 2162) announced that its BCMA×CD3 T cell engager (TCE), CM336 (OM336),...
Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion protein,...
Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance
Bristol-Myers Squibb (BMS, NYSE: BMY) reported first-quarter 2026 revenue of $11.489 billion, representing a 1%...
Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial...
Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has submitted a new indication approval...
Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced it has received clinical trial approval from China’s...
Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced it has received clinical clearance...
Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced the inauguration of its Hong...
Allergan Aesthetics Secures First-in-China NMPA Approval for Juvéderm VOLUMA Temple Indication
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced it has received marketing approval from China’s...
Harbour BioMed Receives FDA Clearance for Phase I Trial of Novel B7H4xCD3 Bispecific Antibody HBM7004
Harbour BioMed (HKG: 2142) announced it has received clearance from the U.S. Food and Drug...
Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic partnership with...
Johnson & Johnson Terminates Two CAR-T Development Programs Amid Portfolio Prioritization
Johnson & Johnson (J&J, NYSE: JNJ) announced the termination of development programs for JNJ-9530, a...
China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
The National Drug Alliance Procurement Office, administrator of China’s volume-based procurement (VBP) program, announced the...
Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
Harbour BioMed (HKG: 2142) announced its participation in a $165 million cross financing round for...
Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has...